# Research Loop Progress

## Current Session: h265 (2026-02-05)

### Session Summary

**Agent Role:** Research Executor
**Status:** Complete
**Hypothesis Tested: 1**
- h265: Drug Class-Based Tier Modifier - **VALIDATED**

### Cumulative Statistics
| Status | Count |
|--------|-------|
| Validated | 151 |
| Invalidated | 52 |
| Inconclusive | 8 |
| Blocked | 18 |
| Deprioritized | 3 |
| Pending | 37 |
| **Total** | **269** |

### KEY SESSION FINDINGS

**h265: Drug Class-Based Tier Modifier - VALIDATED**

Based on h163 precision data, implemented drug class tier modifiers in `production_predictor.py`:

**HIGH-PRECISION BOOSTS (added):**
| Drug Class | Category | Precision | Tier Change |
|------------|----------|-----------|-------------|
| SGLT2 | cardiovascular | 71.4% | → GOLDEN |
| Thiazolidinedione | metabolic | 66.7% | → GOLDEN |
| NSAID | autoimmune | 50.0% | → HIGH |
| Fluoroquinolone | respiratory | 44.4% | → HIGH |

**LOW-PRECISION PATTERNS (implicit demotion):**
- mAb + cancer = 6.2% (sparse GT, not model failure)
- Kinase inhibitor + cancer = 2.8%
- Receptor fusion + cancer = 4.0%

**KEY INSIGHT:** Drug class modifiers improve PRECISION, not R@30.
The value is in confidence tiering for clinical prioritization.

### New Hypotheses Generated
1. **h266**: Drug Class × Rank Interaction (precision)
2. **h267**: Biologic Sparse GT Root Cause (error_analysis)
3. **h268**: NSAIDs vs DMARDs for Autoimmune Subtypes (precision)

### Production Changes
Added to `src/production_predictor.py`:
- SGLT2_INHIBITORS drug set
- THIAZOLIDINEDIONES drug set
- NSAID_DRUGS drug set
- FLUOROQUINOLONE_DRUGS drug set
- Rules in cardiovascular, metabolic, autoimmune, respiratory category rescue

### Recommended Next Steps
1. **h266**: Test drug class × rank interactions (low effort)
2. **h267**: Analyze biologic GT gap (medium effort)
3. **h91**: Literature mining for zero-shot (high effort, high impact)

---

## Previous Sessions

See git history for detailed session notes.
